Maintaining optimal levels of LDL-C during young adulthood and middle age is one way to limit the risk of coronary heart disease.
Nearly 6% of transplant recipients developed cancer within 10 years of the procedure, researchers reported.
Expanded FDA labeling for sacubitril/valsartan could make a massive impact on patient care in the next three years.
The study's authors hope their work can help high-risk patients receive the care they need.
One researcher described the findings, presented at the Heart Failure Society of America's Annual Scientific Meeting, as "great news for patients and clinicians."
"The rise of the delta variant of COVID-19 is a reminder that this pandemic is not over," the president of the Heart Failure Society of America said in a statement.
These findings, one specialist said, could provide a significant piece to "the puzzle of heart development."
The new analysis, published in the New England Journal of Medicine, included data from more than 2.1 million patients.
Additional research is still needed, but researchers may have uncovered a new treatment for heart failure.
The new analysis, which included data from more than 24,000 adult patients, was published in the Journal of the American College of Cardiology.
Detecting heart failure issues early on, one researcher observed, can improve patient care and hospital efficiency at the same time.
The FDA’s decision was based largely on results from a clinical trial that included more than 3,700 heart failure patients with a left ventricular ejection fraction of 40% or less.
SNMMI is among the many organizations that collaborated on the updated guidance for imaging prostate cancer.
Cordis Corporation warned its device can dislodge during procedures and cause serious adverse events such as heart attack or stroke.
Researchers have used machine learning to track diabetes at the population level.